Rocket Pharmaceuticals (NASDAQ:RCKT) shares jumped more than 40% intra-day today after the company announced an agreement with the U.S. FDA regarding the Phase 2 trial of RP-A501.

This trial targets Danon disease, a life-threatening inherited cardiomyopathy. The CEO of Rocket Pharmaceuticals, Gaurav Shah, expressed confidence that this agreement represents a significant step toward efficiently and swiftly providing potential therapy to Danon Disease patients, potentially avoiding the need for heart transplantation or the risk of death.

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

× ¿Cómo puedo ayudarte?